Cullinan Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 2834 cullinantherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Therapeutics, Inc.

Learn Why The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following Trial Clearance - Nov 1st, 2026 1:10 pm
Cullinan Therapeutics (CGEM) Wins Trial Clearance, Is The Upside Already Priced In? - Oct 31st, 2026 1:12 pm
Cullinan Therapeutics (CGEM) Stock May Be Fully Priced Following Trial Progress - Oct 29th, 2026 9:16 am
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect? - Oct 29th, 2026 6:55 am
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA - Oct 27th, 2026 5:00 am
Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases - Oct 19th, 2026 5:00 am
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia - Oct 8th, 2026 5:00 am
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program - Oct 1st, 2026 5:30 pm
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049 - Sep 28th, 2026 5:02 am
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026 - Sep 26th, 2026 4:07 pm
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger - Sep 24th, 2026 1:08 pm
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs - Sep 24th, 2026 7:57 am
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio - Sep 24th, 2026 5:00 am
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data - Sep 24th, 2026 4:12 am
Cullinan Therapeutics (CGEM) Is Down 18.2% After Strong Zipalertinib Phase 3 Lung Cancer Data Release – Has The Bull Case Changed? - Sep 23rd, 2026 10:29 pm
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data - Sep 23rd, 2026 2:12 pm
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum - Sep 21st, 2026 10:00 am
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity? - Sep 16th, 2026 10:00 pm
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results - Sep 14th, 2026 8:09 am
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer - Sep 14th, 2026 5:00 am